NTLA:NASDAQ
Intellia Therapeutics Inc
12,21Â USD
arrow_downward
−4,16%(−0,53) 1 D
12,25Â USD
arrow_upward
+0,33% (+0,040)bedtimeEtter stengetid
Stengt: 9. sep., 16:00:00 GMT-4 · USD
search
Alle symboler
1Â D
5Â D
1Â M
6Â M
I år
1Â Ã…
5Â Ã…
MAKS
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for NTLA …
Ã…pne
12,50Â USD
Høy
12,82Â USD
Lav
12,19Â USD
Markedsverdi
1,71Â mrd.
Snittvolum
3,40Â mill.
Volum
0,00
52 u høy
28,24Â USD
52Â u lav
7,95Â USD
EPS
−3,36 USD
Beta
1,82
Utestående aksjer
140,13Â mill.
Antall ansatte
377
Ã…pne
12,50Â USD
Høy
12,82Â USD
Lav
12,19Â USD
Markedsverdi
1,71Â mrd.
Snittvolum
3,40Â mill.
Volum
0,00
52 u høy
28,24Â USD
52Â u lav
7,95Â USD
EPS
−3,36 USD
Beta
1,82
Utestående aksjer
140,13Â mill.
Antall ansatte
377
Nyhetssaker
Fra nettkilder og nyhetspartnere
Pluang
·
for 15 timer siden
Intellia Therapeutics gains as FDA grants Prior...
Zacks
·
for 16 timer siden
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
Quiver Quantitative
·
for 17 timer siden
Intellia Therapeutics Stock Short Interest Rises to 40.35%
Zacks Investment Research
·
for 17 timer siden
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
Profil
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Om Intellia Therapeutics Inc
Administrerende direktørJohn Leonard
Ansatte377
Grunnlagt2014
HovedkontorCambridge, Massachusetts, USA
Sektor-
Nettstedintelliatx.com